<DOC>
	<DOCNO>NCT02427646</DOCNO>
	<brief_summary>The present study attempt fill critical knowledge gap BoNT A tremor management study efficacy IncobotulinumtoxinA ( Xeomin® ) injection hand tremor essential tremor idiopathic Parkinson disease use data regard composition tremor obtain sophisticated , yet clinically accessible multi-sensor base kinematic information .</brief_summary>
	<brief_title>Use Kinematic Assessment Hand Tremor Pre- Post- Treatment With Botulinum Toxin Type A Essential Tremor Parkinson Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Consenting male female participant , age 18 year 80 year PD individual diagnose UK Brain Bank Criteria stage H &amp; Y23 disease ET hand tremor motor dominant hand Stable IPD/ET medication management 6 month duration prior enrollment study Individuals IPD eligible study tremor primary bothersome symptom determine clinical exam patient report Participants botulinum toxin naïve tremor management History stroke Muscle weakness relate compartmental muscle syndrome Smoking Offending medication ( Lithium , valproate , steroid , amiodarone , betaadrenergic agonist ( e.g . salbutamol ) ) Contradictions per Xeomin® drug monograph Patients prescribe zonisamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Kinematics</keyword>
	<keyword>Botulinum toxin type A</keyword>
</DOC>